Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib + Fulvestrant in HR+/HER2- Advanced Breast Cancer
NCT02422615Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2015
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 30
01
Overview
A Phase 3 trial of ribociclib in breast cancer, sponsored by Novartis. Started Jun 2015; status: completed.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02422615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02422615.